Treatment
Glofitamab + Obinutuzumab clinical trials
We’re tracking 19 recruiting studies that include Glofitamab + Obinutuzumab, each written for real people, not researchers, below.
Recruiting studies
- NCT05861050RecruitingPhase 1/Phase 2
Study of 4-drug treatment for newly diagnosed high-risk mantle cell lymphoma
This trial tests a combination of medicines to treat newly diagnosed high-risk mantle cell lymphoma (MCL). It may help shrink the lymphoma and improve outcomes, especially for people whose disease has higher-risk features.
Duarte, CaliforniaAges 18–80 - NCT06071871RecruitingPhase 2
A trial of 3 drugs before or after CAR-T for lymphoma
This trial tests a combination of three drugs (polatuzumab vedotin, obinutuzumab, and glofitamab) for people with a type of large B-cell lymphoma. It is given either as a bridge treatment before CAR-T cell therapy or to those who did not fully respond to CAR-T.
LondonAges 18 years+ - NCT06054776RecruitingPhase 2
Acalabrutinib, obinutuzumab, and glofitamab for mantle cell lymphoma
This trial tests a combination of three targeted drugs for mantle cell lymphoma that has come back or not responded to prior treatment. It aims to see if this new drug cocktail can work better than standard options.
Duarte, CaliforniaAges 18 years+ - NCT06186648RecruitingPhase 2
Glofitamab with chemo for Richter syndrome
This trial tests a new drug called glofitamab combined with standard chemo-immunotherapy (rituximab or obinutuzumab plus CHOP) for people with Richter syndrome, an aggressive lymphoma that arises from CLL. The goal is to see if the combination is safe and effective.
AmiensAges 18 years+ - NCT06357676RecruitingPhase 1/Phase 2
Glofitamab, Ibrutinib and Obinutuzumab for Untreated Mantle Cell Lymphoma
This trial tests a combination of three drugs (glofitamab, ibrutinib, and obinutuzumab) for people with untreated mantle cell lymphoma. The goal is to see if this combination works better for high-risk or older patients.
Portland, OregonAges 18 years+ - NCT06252675RecruitingPhase 2
Glofitamab and pirtobrutinib for relapsed mantle cell lymphoma
This study tests a combination of two drugs—glofitamab (given as an infusion) and pirtobrutinib (a pill)—for people with mantle cell lymphoma that has come back or not responded to previous treatment. The goal is to see if the combo works better than either drug alone.
Davis, CaliforniaAges 18 years+ - NCT06558604RecruitingPhase 2
Study of glofitamab with venetoclax for high-risk mantle cell lymphoma
This trial tests a new combination of drugs (glofitamab plus venetoclax, with or without zanubrutinib) for people with mantle cell lymphoma that is either newly diagnosed with high risk features, or has come back or not responded to earlier treatments. The goal is to see if these targeted therapies can improve outcomes.
BrugesAges 18–79 - NCT06084936RecruitingPhase 3
Glofitamab alone vs other treatments for mantle cell lymphoma
This trial tests a new drug called glofitamab to see if it works better than other standard treatments for people with mantle cell lymphoma that has come back or not responded to previous therapy. It is for patients who have already tried a BTK inhibitor and at least one other treatment.
Berkeley, CaliforniaAges 18 years+ - NCT06043674RecruitingPhase 2
Glofitamab alone or with other drugs for Richter's transformation
This trial tests a drug called glofitamab, alone or combined with other drugs, for people whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has changed into a faster-growing lymphoma (Richter's transformation). The goal is to see how well these treatments work and which combination might be best.
Atlanta, GeorgiaAges 18 years+ - NCT06213311RecruitingPhase 2
CAR T-cells plus antibody drug for relapsed large B-cell lymphoma
This trial tests two immune-based treatments—first a special type of immunotherapy (CAR T-cells, called axi-cel), then a targeted antibody drug (glofitamab)—for people with large B-cell lymphoma that did not fully respond to their first treatment or came back within a year. The goal is to see if this combination can help more people achieve lasting remission.
Houston, TexasAges 18 years+ - NCT06867536RecruitingPhase 2
Radiation plus glofitamab for relapsed large B-cell lymphoma with large tumors
This trial tests whether combining a short course of radiation with a targeted antibody drug (glofitamab) can help people with aggressive large B-cell lymphoma that came back after treatment, especially if they have bulky tumors. It aims to find a new option for hard-to-treat cases.
Wuhan, HubeiAges 18–75 - NCT05533775RecruitingPhase 1/Phase 2
Study of an antibody medicine with or without chemotherapy for relapsed lymphoma
This trial tests glofitamab alone or with chemotherapy and immunotherapy in children and young adults whose “mature B-cell” non-Hodgkin lymphoma has come back or hasn’t responded to treatment. It looks at whether the study medicines can shrink lymphoma again and are safe enough to use in this age group.
Birmingham, AlabamaAges 6 months–30 years - NCT06806033RecruitingPhase 2
New drug combo for relapsed aggressive B-cell lymphoma
This trial tests a new combination of drugs (glofitamab plus gemcitabine and oxaliplatin) for people with aggressive B-cell lymphoma that has returned or not responded to prior treatment. The goal is to see if this approach can improve outcomes while managing side effects.
Anchorage, AlaskaAges 18 years+ - NCT07003295RecruitingPhase 2
Glofitamab for mantle cell lymphoma that returned after CAR-T
This trial tests a new drug, glofitamab, for mantle cell lymphoma that came back or didn’t respond after CAR-T cell therapy. It aims to see if glofitamab can shrink or control the lymphoma.
Duarte, CaliforniaAges 18 years+ - NCT06634589RecruitingPhase 1/Phase 2
Combination therapy for relapsed B-cell blood cancers
This study tests new drug combinations for people with B-cell blood cancers (like lymphoma or leukemia) that have come back or stopped responding to treatment. It aims to see if these combos are safe and can help fight the cancer.
Phoenix, ArizonaAges 18 years+ - NCT04889716RecruitingPhase 2
CAR-T followed by antibody treatment for lymphoma
This Phase 2 study looks at giving CAR-T cell therapy first, then follow-up “bispecific” antibody medicines to help keep large B-cell lymphoma from coming back. It’s for people whose lymphoma returned or did not respond to prior standard treatments and who still have measurable disease on scans.
Omaha, NebraskaAges 18 years+ - NCT05833763RecruitingPhase 2
Glosfitamab plus pirtobrutinib for mantle cell lymphoma after BTK drugs
This Phase 2 trial tests how well two anti-cancer medicines—glofitamab and pirtobrutinib—work for mantle cell lymphoma (MCL) that has not responded well to prior BTK inhibitor therapy. It may help by shrinking the lymphoma after earlier treatment and checking how safe the combination is for people with similar disease history.
Parkville, VictoriaAges 18 years+ - NCT06765317RecruitingPhase 2
Glofitamab therapy for older adults with diffuse large B-cell lymphoma
This trial tests a new combination therapy using glofitamab for people aged 65 or older with diffuse large B-cell lymphoma who have not received prior treatment. The goal is to see if this approach is safe and effective for patients who are considered too frail for standard therapies.
Basking Ridge, New JerseyAges 65–80 - NCT07240194RecruitingPhase 2
A study of a new drug combo for large B-cell lymphoma with TP53 changes
This trial tests a combination of three drugs (glofitamab, a PD-1 antibody, and lenalidomide) for people with relapsed or refractory large B-cell lymphoma that has a TP53 change. The goal is to see if this combination works better for patients who cannot have a stem cell transplant.
Nanjing, JiangsuAges 18 years+
What Glofitamab + Obinutuzumab is being studied for
Conditions with recruiting Glofitamab + Obinutuzumab studies.
Common questions
- Are there clinical trials studying Glofitamab + Obinutuzumab?
- Yes. Clin2 currently lists 19 recruiting studies that include Glofitamab + Obinutuzumab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Glofitamab + Obinutuzumab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Glofitamab + Obinutuzumab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Glofitamab + Obinutuzumab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.